Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Christie

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Breast (Edinburgh, Scotland)|November 18, 2008
The prone technique for breast irradiation - is it ready for clinical trials?Rory McKinnon, David Christie, Helen Peres, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 6, 2007
PIKfyve in the SGK1 mediated regulation of the creatine transporter SLC6A8Nathalie Strutz-Seebohm, Manzar Shojaiefard, David Christie, et al.
Peerj|June 27, 2017
Focus expansion and stability of the spread parameter estimate of the power law model for dispersal gradientsPeter S Ojiambo, David H Gent, Lucky K Mehra, et al.
Journal of Medical Imaging and Radiation Oncology|October 20, 2011
Smoking habits of radiotherapy patients: did the diagnosis of cancer make an impact and is there an opportunity to intervene?Charlie Chia-Tsong Hsu, Gigi Nga Chi Kwan, Aakriti Chawla, et al.
Pharmacology|April 19, 2018
Prazosin but Not Tamsulosin Sensitises PC-3 and LNCaP Prostate Cancer Cells to DocetaxelBriohny H Spencer, Catherine M McDermott, Russ Chess-Williams, et al.
Prostaglandins & Other Lipid Mediators|February 1, 2020
The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2Shailendra Anoopkumar-Dukie, Tom Conere, Aileen Houston, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2010
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trialDavid Christie, Keith Dear, Thai Le, et al.
Scientific Reports|May 20, 2020
A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapyJordan Hart, Briohny Spencer, Catherine M McDermott, et al.
Journal of Clinical Medicine|October 14, 2022
Drivers of Radioresistance in Prostate CancerLiam King, Nijole Bernaitis, David Christie, et al.
Journal of Medical Imaging and Radiation Oncology|April 29, 2023
Response to: Radiation Oncology Viewpoint: Wide-field radiation therapy for skin cancerisation-Have we forgotten what we learned?Gerald B Fogarty, Elizabeth J Paton, David Schlect, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Breast (Edinburgh, Scotland)|November 18, 2008
The prone technique for breast irradiation - is it ready for clinical trials?Rory McKinnon, David Christie, Helen Peres, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 6, 2007
PIKfyve in the SGK1 mediated regulation of the creatine transporter SLC6A8Nathalie Strutz-Seebohm, Manzar Shojaiefard, David Christie, et al.
Peerj|June 27, 2017
Focus expansion and stability of the spread parameter estimate of the power law model for dispersal gradientsPeter S Ojiambo, David H Gent, Lucky K Mehra, et al.
Journal of Medical Imaging and Radiation Oncology|October 20, 2011
Smoking habits of radiotherapy patients: did the diagnosis of cancer make an impact and is there an opportunity to intervene?Charlie Chia-Tsong Hsu, Gigi Nga Chi Kwan, Aakriti Chawla, et al.
Pharmacology|April 19, 2018
Prazosin but Not Tamsulosin Sensitises PC-3 and LNCaP Prostate Cancer Cells to DocetaxelBriohny H Spencer, Catherine M McDermott, Russ Chess-Williams, et al.
Prostaglandins & Other Lipid Mediators|February 1, 2020
The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2Shailendra Anoopkumar-Dukie, Tom Conere, Aileen Houston, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2010
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trialDavid Christie, Keith Dear, Thai Le, et al.
Scientific Reports|May 20, 2020
A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapyJordan Hart, Briohny Spencer, Catherine M McDermott, et al.
Journal of Clinical Medicine|October 14, 2022
Drivers of Radioresistance in Prostate CancerLiam King, Nijole Bernaitis, David Christie, et al.
Journal of Medical Imaging and Radiation Oncology|April 29, 2023
Response to: Radiation Oncology Viewpoint: Wide-field radiation therapy for skin cancerisation-Have we forgotten what we learned?Gerald B Fogarty, Elizabeth J Paton, David Schlect, et al.
Pageof 6